CAR-T in China: Commercial Products, Trials, and Patient Checkpoints

China’s National Medical Products Administration (NMPA) began approving commercial CAR-T products in 2021. Multiple CD19- and BCMA-targeted products are now marketed for selected relapsed/refractory hematologic malignancies (for example large B-cell lymphoma and multiple myeloma indications on labels). China also hosts a large volume of cell-therapy clinical trials.

International access is real but selective: only a limited set of centers can run apheresis, manufacturing logistics, CRS/ICANS management, and ICU backup. Commercial labeled use, investigator-initiated trials, and Boao special-import pathways are different routes with different eligibility rules. Before travel, confirm indication fit, prior-line documentation, bridging plans, monitoring length, and a written hospital estimate that separates drug cost from ancillary care.